Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 vs Topotecan/Amrubicin in 2nd-line SCLC
NCT01904253Phase 2Terminated
- Sponsor
- Taiho Oncology
- Start
- Jul 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of trifluridine + tipiracil in small cell lung cancer (SCLC), sponsored by Taiho Oncology. Started Jul 2013; status: terminated.
02
Drugs
trifluridine + tipiracil
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01904253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01904253.